France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies
This article was originally published in The Pink Sheet Daily
Executive Summary
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.
You may also be interested in...
Time To Strike On Regenerative Medicine/Stem Cell Companies?
As the hype that accompanied the revelation of regenerative medicine recedes, biotechs that survived the transition from science experiment to market-focused company have now settled into the same realities that face the rest of the industry in terms of making the case for reimbursement and preparing for regulatory scrutiny, not to mention the exit question.
Time To Strike On Regenerative Medicine/Stem Cell Companies?
As the hype that accompanied the revelation of regenerative medicine recedes, biotechs that survived the transition from science experiment to market-focused company have now settled into the same realities that face the rest of the industry in terms of making the case for reimbursement and preparing for regulatory scrutiny, not to mention the exit question.
France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
French industrialists invest in a Series B fundraising for Pharnext, attracted by its network pharmacology approach to neurological and other diseases.